Calico

Phase A — Understand the business

Lens 1 · Company Overview

Calico Life Sciences LLC is an Alphabet-funded (Google-founded, 2013) biotechnology company whose stated mission is to understand the biology of aging and translate it into therapeutics for age-related disease. It was launched in September 2013 with Arthur (Art) Levinson — former Genentech CEO and current Apple chairman — as founding CEO. HQ: South San Francisco, with a wet-lab/comparative-biology operation tied to the Buck Institute for Research on Aging in Novato, CA.

The business model is unusual and is the single most important thing to understand about this name:

• Funding side: Calico is bankrolled by Alphabet (the patient-capital anchor) and, from 2014 to November 2025, by a drug-development partnership with AbbVie. Total committed capital across both reached ~$2.5B by 2018. AbbVie's cumulative contribution was $1.75B from 2013–2022 per AbbVie's 2024 annual report.
• Division of labor (the deal mechanics): Calico ran discovery and early development through ~Phase 2a; AbbVie held an option to in-license, run late-stage development, and lead commercialization. This is a "science engine feeds a commercializer" structure — Calico never had to build a commercial org, but also never owned the back half of the value chain.
• The model just broke. On 2025-11-12, STAT News reported (from internal emails) that AbbVie is ending the 11-year collaboration and Calico is laying off ~100 scientists/chemists. AbbVie's rationale: a strategic shift away from small-molecule discovery (Calico's core) toward biologics, injectables, and genetic medicines. Trigger context: the lead asset fosigotifator failed its ALS readout in Jan 2025 (Lens 5).

Key products/services: No marketed product. Zero drugs approved in 12 years. The "product" is a research platform (yeast, worms, naked mole-rats, computational/aging biology) plus a clinical pipeline (Lens 4/5).

Customers/suppliers/competitors: Calico has no customers (pre-revenue). Its "customer" was effectively AbbVie (the option-holder that would have paid milestones + royalties) — now departed. Suppliers: CDMO/manufacturing partners (e.g., it in-licensed a Mabwell-manufactured antibody — Lens 2). Competitors: the longevity-biotech cohort — Altos Labs, Retro Biosciences, Unity Biotechnology (shuttered Sep 2025), BioAge, Rubedo, Gero (Lens 3/7).

Contract structure / payment terms: The defining contract — the AbbVie option-and-milestone deal — is terminating. Calico's new go-forward contract is the June 2025 Mabwell in-license of an IL-11 antibody: $25M upfront + up to $571M in milestones ex-Greater China. Note the inversion: Calico is now paying to in-license assets rather than receiving option payments — it has flipped from licensor to licensee, a meaningful change in cash dynamics.

Lens 2 · Supply Chain

For a pre-revenue drug-discovery shop the "supply chain" is the discovery → development → manufacture → (would-be) commercialization chain. Named stakeholders along it:

• Capital upstream: Alphabet Inc. (parent/anchor funder) → AbbVie (2014–2025 co-funder + late-stage developer + commercializer — now exiting). This is the chokepoint that just snapped: AbbVie was the single-source commercialization partner, and its departure removes the entire downstream half of the chain.
• Discovery inputs: academic/translational collaborators — Broad Institute (translational-science collaboration), Buck Institute for Research on Aging (comparative-biology / naked mole-rat colony), University of Texas / Rochelle Buffenstein lineage on naked mole-rat work.
• Asset in-sourcing: Mabwell (Shanghai) Bioscience — licensed Calico the IL-11 mAb 9MW3811 (Phase 1, IPF) ex-China; Mabwell retains Greater China + is the originator/likely manufacturer.
• Clinical infrastructure: HEALEY ALS Platform Trial (Mass General) ran the fosigotifator ALS arm (Regimen F, NCT05740813); FDA as gatekeeper (START Pilot, Orphan Drug, Fast Track designations — Lens 5/10).
• Downstream (now vacated): AbbVie was to manufacture-at-scale and commercialize. With AbbVie gone, Calico must either build its own late-stage/commercial infrastructure ("expanding our internal development infrastructure to advance more programs independently" — Calico spokesman) or find new partners.

Chokepoint / single-source flags:

1. Commercialization partner = single-source (AbbVie), now lost. Highest-severity dependency in the whole structure.
2. Capital = single-source (Alphabet). Once AbbVie's co-funding stops, Calico is ~100% dependent on Alphabet's willingness to keep funding a 12-year-old, zero-approval moonshot during an Alphabet cost-discipline era. This is the existential dependency.

Lens 3 · Competitive Advantages (moats)

Durable moats — genuine but narrow:

• Patient, near-infinite capital (historically). Alphabet's balance sheet let Calico pursue basic aging biology on a 10–20 year horizon that no venture-funded biotech could sustain. This is the real moat — time. But it is a moat owned by Alphabet, not by Calico, and it is now conditional (see Lens 13).
• Talent density + science-first culture. Levinson deliberately recruited top scientists without deep aging-medicine backgrounds, betting "good science yields results". CSO David Botstein (a giant of genetics) anchors credibility. ~375–448 employees.
• Comparative-biology data assets. A decade of naked mole-rat, yeast, and worm aging datasets — proprietary and hard to replicate.

Where the moat is weak (this is the crux):

• No commercial moat, no IP cash flow, no switching costs, no network effects, no brand-with-customers — because there are no products and no customers. A research moat that has produced zero approvals in 12 years has not yet converted into anything defensible in the market.
• Bargaining power: collapsing. Pre-2025, Calico had leverage as AbbVie's science feeder. Post-AbbVie, Calico is a price-taker — it in-licenses assets (paying $25M+$571M to Mabwell) rather than commanding option payments. Its bargaining power over future partners is weakened by the public AbbVie walk-away and the fosigotifator failure.

Verdict on moat: A scientific moat (capital horizon + talent + data) that has not translated into a commercial or financial moat. Durable only as long as Alphabet funds it.

Lens 4 · Segments

segments.csv is header-only (research-layer: empty) — Calico discloses no segment, geographic, or financial breakdown (private, unaudited). The only meaningful "segmentation" is by pipeline program, which is the clinical-stage swap and lives in Lens 5. Revenue/EBITDA/earnings by segment: n/a — private, not disclosed. Geographic: HQ South San Francisco + Novato, CA; ex-China rights on the in-licensed IL-11 asset; otherwise undisclosed.

---

Phase B — Measure performance (+clinical / +private swaps applied)

Lens 5 · Pipeline by phase (clinical swap — replaces "Earnings Result") + Funding & valuation trajectory (private swap)

The asset table IS the company. After 12 years: 5 candidates advanced into the clinic, ~20 preclinical candidates, "hundreds" of research papers. Clinical assets (all originally AbbVie-partnered; "ABBV-CLS" prefix denotes the joint programs):

Funding/valuation trajectory (private swap):

• 2013: Founded by Google; Levinson CEO.
• 2014: AbbVie deal, up to $1.5B ($250M each + up to $1B more).
• 2018: Extended, total commitment ~$2.5B.
• 2021: Extended again +$500M each → $3.5B headline collaboration funding (note: "$3.5B" is the headline collaboration ceiling; AbbVie's actual cash deployed 2013–2022 was $1.75B ).
• 2017: Calico + AbbVie had already burned ~$1B. Calico declined to disclose total cash burned since 2013. → Burn rate ``: ~$2.5B+ deployed over ~12 yrs ≈ $200M+/yr gross spend across both funders; unaudited.
• 2025-06: Mabwell IL-11 in-license — Calico now a net payer.
• 2025-11: AbbVie exits; ~100 layoffs.
• Company valuation: n/a — private, wholly Alphabet-controlled, never priced by an external round (PitchBook/Crunchbase show no venture valuation; "raised $2M" entries are data-shop artifacts, not real).

Lens 6 · Founder interviews / narrative sentiment (private swap — replaces "Earnings Calls")

No earnings calls (private). Sentiment is read from public posture, which has shifted markedly:

• 2016–2021 — confident, secretive, long-horizon. "Good science yields results"; Calico was the prestige longevity flagship.
• 2025-01 — first public data, and it failed. STAT's framing: "Google's secretive anti-aging company Calico finally released data. Its drug failed." Insilico's Alex Zhavoronkov called it "very sad news… a big blow for aging research in drug discovery".
• 2025-11 — defensive but defiant. Calico spokesman: "We're deeply appreciative of our partnership with AbbVie, which has played an important role in shaping Calico's clinical development capabilities"; and the company will "continue advancing the development of many of these programs while expanding our internal development infrastructure to advance more programs independently".
• Tone shift = from prestige moonshot → a 12-year-old biotech defending its right to exist after its partner and its lead asset both left. The "stopped saying" tell: gone is the grand lifespan-extension language; the new register is rare-disease clinical pragmatism (ADPKD, VWM, IPF).

Lens 7 · Catalyst calendar + mechanism comps (clinical swap) + Cap table / IPO-proximity (private swap)

Catalyst calendar (what de-risks or kills each program, and when):

Mechanism comps (by target, not by P/E — clinical swap):

• ADPKD (the lead): competes with tolvaptan (Otsuka's Jynarque — the only approved ADPKD drug, but tolerability-limited) and a thin pipeline; PAPP-A/IGF mechanism is differentiated and first-in-class — genuinely novel. This is the most investable angle in the whole name.
• eIF2B/ISR (fosigotifator): competes with Denali's similar ISR program (STAT noted the comparison) — and Denali context matters because the mechanism class took a hit with the ALS miss.
• PTPN2 I-O: competes broadly in checkpoint-potentiation — crowded, early.
• IL-11 anti-fibrotic: competes with the Enleofen/Boehringer IL-11 franchise and IPF incumbents (nintedanib, pirfenidone).

Cap table / IPO-proximity (private swap):

• No external cap table. Wholly Alphabet-controlled; no tier-1 VC syndicate, no crossover funds (Fidelity/T. Rowe/Coatue), no secondary marks. The crossover-fund IPO-proximity tell that the +private lens looks for is absent — there is no sign of an IPO path.
• IPO-readiness: LOW / undefined. No S-1 milestones, no banker noise, no reason for Alphabet (which consolidates Calico in "Other Bets") to IPO a pre-approval biotech into a hostile 2025–26 longevity-funding winter. Path-to-tradeable: n/a — there is none on the visible horizon. (private-watch.json absent — nothing to write back.)

Lens 8 · Funding / product events that moved the narrative (private swap — replaces "Stock-Price Catalysts")

No stock, so the analog is narrative-moving events over ~5 years:

• 2018-06-26 — Alphabet+AbbVie add $1B → $2.5B total: peak-credibility moment.
• 2021 — extension to $3.5B headline: last vote of confidence from AbbVie.
• 2023-10 — ABBV-CLS-484 Nature publication (preclinical I-O): scientific high-water mark.
• 2025-01-06 — fosigotifator ALS failure: the inflection from prestige to doubt.
• 2025-06-26 — Mabwell IL-11 in-license: signal of a pivot to in-licensing + independence.
• 2025-11-05 — ADPKD Orphan Drug Designation: a rare positive.
• 2025-11-12 — AbbVie exits + ~100 layoffs: the defining negative event.

Pattern: the narrative reacts to clinical data (binary) and partner/capital commitment — exactly what you'd expect; there is no "stock," so the "market" here is the scientific/biotech press and, ultimately, Alphabet's internal capital committee.

---

Phase C — Judge people & books (+ Science & exclusivity sub-section per clinical overlay)

Lens 9 · Management

• Art Levinson — Founder & CEO (since Sep 2013). Track record: elite. Genentech CEO 1995–2009; shepherded Herceptin, Avastin, Rituxan; Institutional Investor "America's Best CEO" (biotech) four straight years 2004–2007; current Apple chairman; former Roche board. One of the most credentialed operators in biotech history.
• Tenure & skin in the game: 12+ years at the helm. Insider ownership: n/a — private Alphabet subsidiary; no equity disclosure. Levinson's "skin" is reputational, not a disclosable stake.
• Capital-allocation history — the uncomfortable part. Levinson's Genentech record is sterling, but at Calico the capital-allocation scorecard after 12 years and ~$2.5B is: zero approvals, one public Phase 2/3 failure, and the loss of the commercialization partner. The strategy — fund deep basic aging science and let approvals emerge — has not yet produced a return-bearing asset. Whether that's "patient science not yet ripe" or "capital misallocation" is the central bull/bear axis (Lens 12/13).
• CSO David Botstein — legendary geneticist; anchors scientific credibility.
• Red flags: Notorious secrecy (STAT repeatedly: "secretive") — opacity is a governance flag in itself. Founder-as-permanent-CEO with no external accountability (no public board, no shareholders) means no market discipline on a 12-year burn. Loss of Hal Barron (R&D head) to GSK in 2017 was an early talent-retention signal.
• Archetype: Scientist-statesman / founder-operator running a corporate-venture moonshot, not a capital-disciplined biotech CEO. Implication for this stage: superb at attracting talent and tolerating long timelines; structurally insulated from the accountability that forces hard pipeline-prioritization — which is exactly what the AbbVie exit now imposes from outside.

Lens 10 · Forensic Red Flags + Regulatory findings

Forensic accounting: n/a in the traditional sense — Calico publishes no income statement, balance sheet, or cash-flow statement (private, unaudited; research-layer financials empty). The forensic concern therefore re-points (per the clinical overlay) to trial-design integrity, going-concern, and program-prioritization honesty:

• Going-concern / runway: The relevant red flag is funding continuity, not receivables. With AbbVie's co-funding ending, Calico's runway is now a single-point bet on Alphabet's annual budget — and Alphabet has been in visible cost-discipline mode across "Other Bets." This is the dominant risk on the "books."
• Trial-design / disclosure: The fosigotifator ALS program used the HEALEY adaptive platform (reputable) and Calico did disclose the failure rather than bury it — a positive integrity mark against the secrecy reputation. No evidence of trial-design manipulation.
• SBC / dilution: n/a — no public equity.

Regulatory findings (required sub-section). Per the pre-fetched regulatory/regulatory-findings.md (2026-06-20):

• SEC (EDGAR LR + AAER): 0 findings. Calico has no CIK and is not an SEC filer — no EDGAR enforcement search is possible.
• Non-SEC (FTC/DOJ/FDA/CFPB): Web search ("Calico" (FTC OR DOJ OR FDA OR... ) enforcement) returns no material enforcement actions, consent decrees, fines, or penalties. On the contrary, FDA interactions are favorable (START Pilot, Orphan Drug, Fast Track for ABBV-CLS-628).
• Item 3 Legal Proceedings: n/a — no 10-K (private).
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER, 0 results — no CIK), web search, and the absence of any SEC 10-K, as of 2026-06-20. Findings are unaudited per public sources.

Science & exclusivity (clinical-overlay sub-section)

• Mechanism validation: Mixed. The eIF2B/ISR mechanism (fosigotifator) is now partially de-validated in ALS (clinical miss). The anti-PAPP-A/IGF mechanism (ABBV-CLS-628) is validated preclinically across three ADPKD mouse models and is plausibly first-in-class — the strongest scientific story in the portfolio. PTPN2/N1 (-484) has a Nature-published preclinical foundation. IL-11 anti-fibrotic biology is well-supported in the literature.
• Scientific-founder / KOL credibility: Top-tier (Levinson, Botstein, Broad/Buck collaborations).
• IP estate / exclusivity: Composition-of-matter on novel small molecules + the in-licensed antibody; specifics undisclosed (private) — patent-cliff timing n/a. Orphan Drug Designation on ABBV-CLS-628 confers 7 years US market exclusivity if approved — a real, if conditional, exclusivity asset.
• Payer/reimbursement path: Only relevant near-term for ADPKD (orphan pricing power, tolvaptan as the priced comparator) — favorable if it reaches approval, but that's years out.

---

Phase D — Project & stress-test

Lens 11 · rNPV + runway-to-catalyst (clinical swap) + IPO-readiness (private swap)

This is not an EPS company — there is no P&L to project. The clinical-overlay output is rNPV of the lead asset + the runway-to-catalyst question; the private-overlay output is path-to-tradeable (there is none).

rNPV — lead asset ABBV-CLS-628 (ADPKD) — illustrative ``, every input labeled:

• US ADPKD addressable population ~140k diagnosed/treated-eligible; orphan-priced antibody. Peak-sales ``: ~$1–2B (vs. Jynarque/tolvaptan franchise, which has done >$1B; a better-tolerated first-in-class could capture meaningful share).
• PoS ``: ~25–35% for a Phase 2 antibody in a genetically-defined orphan indication with Fast Track.
• Discount ~12%; time-to-launch ~2030–2031.
• Illustrative rNPV ``: ~$0.5–1.0B for -628 alone. This is the single asset that could justify Calico-as-a-biotech independent of the aging halo.
• All other programs (VWM, PTPN2, IL-11): early/optionality, rNPV not separately estimable from public data — n/a.

Runway-to-catalyst (the question that actually matters): Does cash reach the ADPKD Phase 2 readout (~2027–2028)? Calico's runway is now entirely a function of Alphabet's continued funding post-AbbVie. n/a — not disclosed; binary on Alphabet's budget decision. This is the crux of the whole dossier: the science could be fine and the company still ends if Alphabet declines to keep funding a 12-year, zero-approval Other Bet.

IPO-readiness / path-to-tradeable (private swap): LOW — effectively none on the visible horizon. Wholly Alphabet-controlled, no external round, no S-1 signal, hostile longevity-funding tape (2025 was the lowest longevity investment since 2019 ). For Connor's tradeable universe, Calico is currently un-investable directly — the only liquid expression is Alphabet (GOOGL), where Calico is an immaterial Other Bet line.

(No Brier forecast logged — forecast.ts create is skipped in watchlist mode and there is no scoreable EPS/binary I'd commit to from web-only grounding. If forced to one binary: "ABBV-CLS-628 ADPKD Phase 2 meets primary endpoint" — I'd put p≈0.30, but I am NOT logging it given the thin grounding and undisclosed readout date.)

Lens 12 · Bull vs Bear

Bull case. Strip away the aging-moonshot narrative and you have a rare-disease biotech with a genuinely differentiated, first-in-class anti-PAPP-A antibody (ABBV-CLS-628) in a 240-patient Phase 2 for ADPKD, carrying Orphan Drug + Fast Track, backed by Alphabet's balance sheet and the best management pedigree in biotech (Levinson/Botstein). ADPKD is a large, under-served orphan market where the only incumbent (tolvaptan) is tolerability-limited. The AbbVie exit, while ugly, frees Calico to own its assets fully — it no longer hands the back-half economics to a partner, and it has signaled an in-licensing/independence strategy (Mabwell IL-11). If -628 reads out positive, Calico becomes a real, ownable drug company with first-in-class economics — and a decade of aging-biology data as a free option on the next platform.

Bear case (2–3 permanent-impairment risks). (1) Capital dependency on a single insulated funder. AbbVie's exit removes co-funding and external validation; Calico now lives or dies on Alphabet's appetite to keep funding a 12-year, zero-approval Other Bet in a cost-discipline era — that decision could permanently impair the business overnight, independent of the science. (2) A 12-year, ~$2.5B track record of zero approvals and one public Phase 2/3 failure is the base rate, and it is bad; longevity drug development has never delivered an aging-indication approval. (3) The surviving pipeline is thin and mostly early — outside ADPKD, the assets are Phase 1 or salvage-mode; one ADPKD miss leaves very little.

Pre-mortem (18 months out, thesis broke): Most likely failure mode — Alphabet, mid-cost-discipline and with no commercialization partner to share the burn, ratchets Calico's budget down or winds it toward a "harvest the assets" mode; the ADPKD Phase 2 either disappoints or simply hasn't read out, and Calico shrinks into an asset-holding shell. Secondary mode: ADPKD Phase 2 misses, removing the one investable pillar.

Are multiples too high? No multiple exists (private, unpriced). But the implied bar is high: Alphabet has sunk ~$2.5B; for that to look rational ex-post, Calico needs at least one approval, and the only near-term shot is ADPKD years away.

Contrarian view (what the market refuses to see): The consensus reads "AbbVie walked = Calico is dying." The non-obvious read is that Calico is quietly de-mooning — shedding the unfundable lifespan-extension fantasy and converging on a concrete, first-in-class orphan-antibody company (ADPKD/IPF/VWM) that is far more investable than the "cure aging" story ever was. The death of the narrative may be the birth of an actual biotech. But that only matters to a public investor if Alphabet ever lets it trade — which is the part the bulls hand-wave.

Lens 13 · Devil's Advocate (short-seller)

I am dismantling the bull case.

• What structurally breaks the model: It already broke. The entire downstream half of the value chain (AbbVie: late-stage dev + commercialization + co-funding) just walked, and Calico has never built commercial infrastructure. "We'll expand internal development infrastructure" is a press-release answer to a structural hole that takes years and hundreds of millions to fill — money only Alphabet can supply, and Alphabet is cutting.
• Revenue concentration: There is no revenue — but funding concentration is ~total on Alphabet now. One budget meeting can end this company. No external shareholders means no constituency fighting to keep it alive if Alphabet loses interest.
• Why the moat is weaker than bulls think: The "patient capital" moat is Alphabet's, not Calico's, and it's conditional. The "talent/science" moat produced zero approvals in 12 years. A moat that hasn't monetized in over a decade isn't a moat — it's a cost center with good PR.
• Most dangerous competitor bulls underestimate: Not Altos or Retro — it's Otsuka (tolvaptan) in the one indication that matters (ADPKD), which has the incumbency, the prescriber relationships, and reformulation optionality to blunt a better-tolerated entrant; and the base rate of orphan Phase 2 antibodies that miss.
• Worst capital-allocation: ~$2.5B deployed, zero approvals, lead asset failed, partner gone. By any external-discipline standard this is value destruction; it survives only because the funder is a trillion-dollar parent that doesn't have to mark it to market.
• Assumptions that must hold for "value": (1) Alphabet keeps funding for years; (2) ADPKD Phase 2 hits; (3) Calico can build or partner the commercial back-half it just lost. All three, simultaneously.
• 20–30% disappointment scenario: If ADPKD efficacy underwhelms by 20–30% on cyst-volume/eGFR, the asset likely fails the bar vs. tolvaptan's known profile → the one investable pillar collapses, leaving early-stage optionality and an aging-data library Alphabet may not fund to exploit.
• Single scenario that permanently impairs: Alphabet decides Calico is a sunk-cost Other Bet and winds it down to an IP-holding shell — fully plausible (Unity, a public peer, shuttered in Sep 2025; the whole longevity sector is in a funding winter). Plausibility: moderate-to-high over 2–4 years.

Lens 14 · Management Questions (ordered by information value)

1. Now that AbbVie has exited, what is Alphabet's explicit multi-year funding commitment to Calico — is there a board-approved budget runway through the ADPKD Phase 2 readout, and under what conditions does Alphabet stop funding? (The single answer that most changes the view.)
2. For ABBV-CLS-628 (ADPKD), what is the expected Phase 2 topline date, the pre-specified efficacy bar (cyst-volume/eGFR), and what result would you consider a clear go to Phase 3?
3. Without a commercialization partner, how do you intend to fund and execute late-stage development and commercial build-out — internal build, new pharma partner, or out-license? On what timeline?
4. After 12 years and ~$2.5B with zero approvals, what specifically has changed in your operating model to make the next 5 years convert science into approvals?
5. Which programs survive the post-AbbVie prioritization, and which are being discontinued as part of the ~100-person reduction?
6. What did the fosigotifator ALS failure teach you about the eIF2B/ISR mechanism, and does it change conviction in the VWM indication?
7. Is an eventual IPO or spin-out of Calico (or of a specific asset like -628) on the table, and what milestones would trigger it?
8. What are the terms and rationale of the Mabwell IL-11 deal — why in-license now, and is in-licensing the new core strategy vs. internal discovery?
9. What is Calico's current cash position and net annual burn, and how many months of runway does it represent at the post-layoff cost base?
10. Who owns the IP and program rights to the ABBV-CLS assets post-AbbVie — does Calico hold them cleanly, and are there any reversion/royalty obligations to AbbVie?
11. How do you think about ADPKD competition from Otsuka/tolvaptan and any reformulations — what's your differentiation beyond tolerability?
12. What is the regulatory path and timeline for -628 given Fast Track + Orphan Drug — could you reach accelerated approval, and on what endpoint?
13. How will the ~100-person layoff affect discovery throughput and the comparative-biology platform (naked mole-rat / Buck Institute work) that defines Calico's research identity?
14. What is the succession plan for the CEO and CSO roles, and how is the board (such as it is) structured to provide accountability as a wholly-owned subsidiary?
15. Of the ~20 preclinical candidates, which 2–3 are the next to enter the clinic, and what de-risks them enough to justify the spend in the current environment?

---